EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Zhu, Shaojun ^a   Chu, Dake ^b,c   Zhang, Yang ^c   Wang, Xuxia ^a   Gong, Li ^a   Han, Xiujuan ^a   Yao, Li ^a   Lan, Miao ^a   Li, Yanhong ^a   Zhang, Wei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CD147; Colorectal cancer; Disease free survival

Indexed keywords

CD147 ANTIGEN; BSG PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR INVASION; AGED; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD147; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873330496     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0369-7     Document Type: Article

References (26)

1. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366-78.
2. Wang J. Current and future situation of colorectal carcinoma screening. J Dig Surg. 2006;5:303-5.
3. Wolpin BM, Meyerhardt JA, Mamon HJ, et al. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168-85.
4. Gabison EE, Mourah S, Steinfels E. Differential expression of extracellular matrix metalloproteinase inducer (CD147) in normal and ulcerated corneas. Am J Pathol. 2005;166:209-19.
5. Yu XL, Hu T, Du JM, et al. Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem. 2008;283:18056-65.
6. Luo J, Teplyakov A, Obmolova G, et al. Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping. Proteins. 2009;77:1009-14.
7. Nakamura K, Kodama J, Hongo A, Hiramatsu Y. Role of EMMPRIN in endometrial cancer. BMC Cancer. 2012;12:191.
8. Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase dependent generation of soluble EMMPRIN. Mol Cancer Res. 2004;2:73-80.
9. Vignesw N, Beckers S, Waigel S, et al. Increased EMMPRIN (CD147) expression during oral carcinogenesis. Exp Mol Pathol. 2006;80:147-59.
10. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621-30.
11. Gabison EE, Hoang-Xuan T, Mauviel A, et al. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie. 2005;87:361-8.
12. Gu J, Zhang C, Chen R, et al. Clinical implications and prognostic value of EMMPRIN/CD147 and MMP2 expression in pediatric gliomas. Eur J Pediatr. 2009;168:705-10.
13. Nishibaba R, Higashi Y, Su J, et al. CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase. J Dermatol. 2012;39:63-7.
14. Zhong X, Li M, Nie B, et al. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 Pulmonary Adenocarcinoma. Ann Surg Oncol. 2012 May 17.
15. Bi XC, Liu JM, He HC, et al. Extracellular matrix metalloproteinase inducer: a novel poor prognostic marker for human seminomas. Clin Transl Oncol. 2012;14:190-6.
16. Piao S, Zhao S, Guo F, et al. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol. 2012;138:627-35.
17. Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 2011;11:312.
18. Afonso J, Longatto-Filho A, Baltazar F, et al. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis. Eur J Surg Oncol. 2011;37:811-7.
19. Liu F, Cui L, Zhang Y, et al. Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma. Breast Cancer Res Treat. 2010;124:677-88.
20. Stenzinger A, Wittschieber D, von Winterfeld M, et al. High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol. 2012 Mar 12.
21. Zhu S, Li Y, Mi L, et al. Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 2011;56:3569-76.
22. Fan Y, Meng S, Wang Y, et al. Visfatin/PBEF/Nampt induces EMMPRIN and MMP-9 production in macrophages via the NAMPT-MAPK (p38, ERK1/2)-NF-κB signaling pathway. Int J Mol Med. 2011;27:607-15.
23. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res. 2005;65:3193-9.
24. Marieb EA, Zoltan-Jones A, Li R, et al. EMMPRIN promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res. 2004;64:1229-32.
25. Yang JM, O'Neill P, Jin W, et al. Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem. 2006;281:9719-27.
26. Pan Y, He B, Song G, et al. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol Rep. 2012;27:2003-9.